Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - dienogest, quantity: 2 mg; ethinylestradiol, quantity: 0.03 mg - tablet, sugar coated - excipient ingredients: calcium carbonate; ferric oxide; macrogol 6000; glycol montanate; glycerol; sucrose; lactose monohydrate; maize starch; povidone; titanium dioxide; purified talc; magnesium stearate - valette is indicated for use as an oral contraceptive and in the treatment of mild to moderate acne in women who seek oral contraception.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - drospirenone,ethinylestradiol -

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - levonorgestrel, quantity: 0.05 mg; ethinylestradiol, quantity: 0.03 mg - tablet, sugar coated - excipient ingredients: purified talc; glycol montanate; lactose monohydrate; povidone; magnesium stearate; sucrose; calcium carbonate; maize starch; macrogol 6000 - oral contraception.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - cyproterone acetate, quantity: 2 mg; ethinylestradiol, quantity: 35 microgram - tablet, sugar coated - excipient ingredients: povidone; calcium carbonate; maize starch; sucrose; lactose monohydrate; macrogol 6000; purified talc; magnesium stearate; glycol montanate - diane-35 ed is indicated for: the treatment of signs of androgenisation in women, such as severe acne (involving inflammation or nodularity or risk of scarring) where prolonged oral antibiotics or local treatment alone has not been successful, or idiopathic hirsutism of mild to moderate degree. diane-35 will also provide effective oral contraception in this patient group. it should not be used in combination with other hormonal contraceptives (see contraindications).,if the hirsutism has only recently appeared or has lately intensified to a considerable extent the cause (androgen-producing tumour or an adrenal-enzyme defect) must be clarified by differential diagnosis.

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - ethinylestradiol; gestodene - coated tablets - ethinylestradiol 0.020 mg; gestodene 0.075 mg - gestodene and estrogen - gestodene and estrogen - contraceptive.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - desogestrel, quantity: 150 microgram; ethinylestradiol, quantity: 30 microgram - tablet - excipient ingredients: povidone; titanium dioxide; magnesium stearate; maize starch; hypromellose; polysorbate 80; triacetin; indigo carmine aluminium lake; colloidal anhydrous silica; iron oxide yellow; lactose monohydrate - oral contraception

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - ethinylestradiol 30ug; levonorgestrel 150ug - tablet - active: ethinylestradiol 30ug levonorgestrel 150ug excipient: calcium carbonate glycerol glycol montanate iron oxide yellow lactose monohydrate macrogol 6000 magnesium stearate maize starch povidone   purified talc   sucrose titanium dioxide calcium carbonate glycol montanate lactose monohydrate macrogol 6000 magnesium stearate maize starch povidone   purified talc   sucrose - oral contraception.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - estradiol valerate 3mg; dienogest 2mg; estradiol valerate 2mg; dienogest 3mg; estradiol valerate 2mg; estradiol valerate 1mg - film coated tablet - active: estradiol valerate 3mg excipient: hypromellose iron oxide yellow lactose monohydrate macrogol 6000 magnesium stearate maize starch povidone pregelatinised maize starch purified talc titanium dioxide active: dienogest 2mg estradiol valerate 2mg excipient: hypromellose iron oxide red lactose monohydrate macrogol 6000 magnesium stearate maize starch povidone pregelatinised maize starch purified talc titanium dioxide active: dienogest 3mg estradiol valerate 2mg excipient: hypromellose iron oxide yellow lactose monohydrate macrogol 6000 magnesium stearate maize starch povidone pregelatinised maize starch purified talc titanium dioxide active: estradiol valerate 1mg excipient: hypromellose iron oxide red lactose monohydrate macrogol 6000 magnesium stearate maize starch povidone pregelatinised maize starch purified talc titanium dioxide hypromellose lactose monohydrate magnesium stearate maize starch povidone pregelatinised maize starch purified talc titanium dioxide - oral contraception.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - drospirenone 3mg (micro 15); ethinylestradiol betadex clathrate 0.02mg (ethinylestradiol betadex clathrade amount equivalent ethinylestradiol 0.02mg) - tablet - 3mg/0.02mg - active: drospirenone 3mg (micro 15) ethinylestradiol betadex clathrate 0.02mg (ethinylestradiol betadex clathrade amount equivalent ethinylestradiol 0.02mg) excipient: lactose monohydrate magnesium stearate maize starch opadry pink 02a34744 hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose purified talc titanium dioxide hypromellose lactose monohydrate magnesium stearate maize starch povidone purified talc titanium dioxide - yaz is indicated for use as: - an oral contraceptive. - treatment of moderate acne vulgaris in women who seek oral contraception. - treatment of symptoms of premenstrual dysphoric disorder (pmdd) in women who have chosen oral contraceptives as their method of birth control. the efficacy of yaz for pmdd was not assessed beyond 3 cycles. yaz has not been evaluated for treatment of pms (premenstrual syndrome).

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - ethinylestradiol, quantity: 20 microgram; drospirenone, quantity: 3 mg - tablet, uncoated - excipient ingredients: magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; purified talc; microcrystalline cellulose - yaz is indicated for use as: - an oral contraceptive. - treatment of moderate acne vulgaris in women who seek oral contraception - treatment of symptoms of premenstrual dysphoric disorder (pmdd) in women who have chosen oral contraceptives as their method of birth control. the efficacy of yaz for pmdd was not assessed beyond 3 cycles. yaz has not been evaluated for treatment of pms (premenstrual syndrome), see clinical trials.